Antibiotics are currently the most used antibacterial treatment for killing bacteria. However, bacteria develop resistance when continually overexposed to antibiotics. Developing antimicrobial agents that can replace existing antibiotics is essential because antibiotic-resistant bacteria have resistance mechanisms for all current antibiotics and can promote nosocomial infections. To address this challenge, in this study, we propose graphene oxide/copper (GO/Cu) nanocomposites as antibacterial materials that can replace the existing antibiotics. GO/Cu nanocomposites are characterized by transmission electron microscopy and scanning electron microscopy. They show that copper (Cu) nanoparticles are well-grown on the graphene oxide sheets. Additionally, a microdilution broth method is used to confirm the efficacy of the antimicrobial substance against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa (P. aeruginosa), which are frequently implicated in nosocomial infections. Specifically, 99.8% of MRSA and 84.7% of P. aeruginosa are eliminated by 500 µg/mL of GO/Cu nanocomposites. Metal nanocomposites can eradicate antibiotic-resistant bacteria by releasing ions, forming reactive oxygen species, and physically damaging the bacteria. This study demonstrates the potential of antibacterial GO/Cu nanocomposites in eradicating antibiotic-resistant bacteria.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3791/66762 | DOI Listing |
J Vis Exp
October 2024
School of Integrative Engineering, Chung-Ang University; Feynman Institute of Technology, Nanomedicine Corporation;
Antibiotics are currently the most used antibacterial treatment for killing bacteria. However, bacteria develop resistance when continually overexposed to antibiotics. Developing antimicrobial agents that can replace existing antibiotics is essential because antibiotic-resistant bacteria have resistance mechanisms for all current antibiotics and can promote nosocomial infections.
View Article and Find Full Text PDFInt J Nanomedicine
August 2024
Department of Plastic Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, People's Republic of China.
Purpose: The treatment of craniofacial bone defects caused by trauma, tumors, and infectious and degenerative diseases is a significant issue in current clinical practice. Following the rapid development of bone tissue engineering (BTE) in the last decade, bioactive scaffolds coupled with multifunctional properties are in high demand with regard to effective therapy for bone defects. Herein, an innovative bone scaffold consisting of GO/Cu nanoderivatives and GelMA-based organic-inorganic hybrids was reported for repairing full-thickness calvarial bone defect.
View Article and Find Full Text PDFSci Rep
July 2024
Department of Chemistry, Khalifa University of Science and Technology, P.O. Box 127788, Abu Dhabi, UAE.
Int J Biol Macromol
March 2024
Department of Anesthesia Techniques, Al-Noor University College, Nineveh, Iraq.
The study focused on creating a novel and environmentally friendly nanocatalyst using cellulose (Cell), β-Cyclodextrin (BCD), graphene oxide (GO), CuO, and FeO.The nanocatalyst was prepared by embedding GO and CuO into Cell-BCD hydrogel, followed by the in-situ preparation of FeO magnetic nanoparticles to magnetize the nanocomposite. The effectiveness of this nanocatalyst was evaluated in the one-pot, three-component symmetric Hantzsch reaction for synthesizing 1,4-dihydropyridine derivatives with high yield under mild conditions.
View Article and Find Full Text PDFNanoscale Adv
December 2023
Department of Pharmaceutical Sciences and Health Outcomes, The Ben and Maytee Fisch College of Pharmacy, University of Texas at Tyler Tyler TX 75799 USA
This study demonstrates the copper nanocomposite-induced enzymatic inhibition of human angiotensin I-converting enzyme-2 (hACE-2) by complex stabilization through the formation of the enzyme nanocomposite. The immediate application of this work is related to ACE-2 as a mechanism of SARS-CoV-2 entry into cells. Moreover, ACE-2 enzyme regulation is a potential therapeutic strategy in hypertension and cardiovascular disease, diabetes, lung injury, and fibrotic disorders.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!